Distribution partnership with MBA SURGICAL EMPOWERMENT

Tampere, Finland, 3 October 2025—Marginum, a Finnish medical technology company specialising in fluorescence-based tissue monitoring systems, has signed an exclusive distribution agreement with MBA SURGICAL EMPOWERMENT, a leading Spanish company in medical and surgical technology. Through this partnership, Marginum brings its HIVEN® device to Spain and Portugal, offering neurosurgeons an innovative tool to make brain cancer surgeries safer and more effective.
 
HIVEN® is intended for the treatment of high-grade gliomas such as glioblastoma, a disease that affects more than 2,000 patients on the Iberian Peninsula every year. With the support of MBA SURGICAL EMPOWERMENT’s extensive commercial and clinical network, Marginum will expand access to its groundbreaking technology, benefiting patients, surgeons and hospitals alike.

“The agreement with MBA SURGICAL EMPOWERMENT marks an important milestone in our international expansion,”, said Samu Lehtonen MD, CEO of Marginum. “Their expertise, strong presence in Spain and Portugal, and deep commitment to neurosurgery make them an ideal partner to bring HIVEN® to the Iberian Peninsula. Together, we aim to set a new standard in the neurosurgical treatment of gliomas.”

Support for high-risk surgeries

Founded in Kuopio in 2020 by a team of surgeons and engineers, Marginum develops data-driven solutions to optimise surgical outcomes without disrupting existing workflows. Its HIVEN® device, which has just obtained the CE mark, has been specifically designed to support neurosurgeons in high-risk procedures such as brain tumour surgery.
 
During these procedures, fluorescence induced by the drug 5-ALA is used to differentiate tumour tissue from healthy tissue. However, this technique has limitations related to the visibility of fluorescent regions and the identification of delicate anatomical structures under blue light, which is necessary to visualise the fluorescent agent. HIVEN® provides an objective, real-time response: it emits an acoustic signal when it detects fluorescence in the aspirated tissue, helping the surgeon to resect with greater precision, especially at the margins of the tumour, where the fluorescence is not as clearly visible.

Benefits for surgeons, patients and hospitals

The novel aspirate tissue monitoring (ATM) approach aims to provide significant advantages over the traditional visual method based on user feedback:

• Greater performance for the surgeon, increasing objectivity in the detection of fluorescent tissue.
• Greater safety for the patient, reducing the risk of damage to blood vessels and cranial nerves.
• Optimisation of tumour tissue resection.
• Fewer reoperations and, therefore, lower hospital costs

With this agreement, MBA SURGICAL EMPOWERMENT reinforces its commitment to providing healthcare professionals with the most advanced technologies to improve outcomes and patient safety. The collaboration also aligns with Marginum’s long-term growth strategy – building a global network of partners who share its mission of supporting surgeons with intuitive, data-driven solutions.

“The alliance with Marginum allows us to add a solution with a real impact on brain cancer surgery to our catalogue. We are convinced that HIVEN® will mark a turning point in this field,” said Carlos Pinto, CEO of MBA SURGICAL EMPOWERMENT.

Additional information:

Samu Lehtonen MD
CEO, Marginum Ltd
samu.lehtonen@marginum.com
+358 40 579 7890

María Carrió 
Communication Manager, MBA Incorporado S.L.U
mariacarrio@mba.eu 
+34 985 19 55 05
 
Marginum is a Finnish medical technology company founded in 2020 and a leading innovator in fluorescence-guided oncological surgery, developing optical tissue monitoring systems. The CE-marked HIVEN® by Marginum enables safe and efficient monitoring of tumour tissues during cancer surgery by seamlessly integrating into existing surgical workflows. Marginum’s vision is to enable surgeons worldwide to perform safer, more precise operations and ultimately improve patient survival and quality of life. www.marginum.com

MBA SURGICAL EMPOWERMENT (trademark of MBA Incorporado S.L.U.) is a leading Spanish company in the medical-surgical technology sector, part of the AddLife Group, whose objective is to provide medical professionals with the most innovative and comprehensive solutions in the fields of orthopaedics, traumatology, neurosurgery, anaesthesia, surgery and oncology. Its purpose is to contribute to the well-being of society by improving the quality of life of patients. In addition, the sustainability of its operations is also one of its priorities. With 37 years of experience in the surgical and healthcare field and a national and international presence, with operational headquarters in Spain and Portugal, MBA SURGICAL EMPOWERMENT works with the leading manufacturers in the sector, has 300 employees and distributes more than 20,000 references, from 100 different products, which it markets to more than 850 hospitals through its 15 sales offices. www.mba.eu

Published in:

• Redacción Médica 2025 ‚Llega a España un innovador dispositivo de cirugía oncológica cerebral‘ https://www.redaccionmedica.com/secciones/tecnologia/llega-a-espana-un-innovador-dispositivo-de-cirugia-oncologica-cerebral-6131